Duration of immune protection of SARS-CoV-2 natural infection against reinfection
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Duration of immune protection of SARS-CoV-2 natural infection against reinfection
Authors
Keywords
-
Journal
JOURNAL OF TRAVEL MEDICINE
Volume -, Issue -, Pages -
Publisher
Oxford University Press (OUP)
Online
2022-10-01
DOI
10.1093/jtm/taac109
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Waning mRNA-1273 Vaccine Effectiveness against SARS-CoV-2 Infection in Qatar
- (2022) Laith J. Abu-Raddad et al. NEW ENGLAND JOURNAL OF MEDICINE
- Effectiveness of mRNA-1273 and BNT162b2 Vaccines in Qatar
- (2022) Laith J. Abu-Raddad et al. NEW ENGLAND JOURNAL OF MEDICINE
- Protection against the Omicron Variant from Previous SARS-CoV-2 Infection
- (2022) Heba N. Altarawneh et al. NEW ENGLAND JOURNAL OF MEDICINE
- SARS-CoV-2 reinfections: Overview of efficacy and duration of natural and hybrid immunity
- (2022) Stefan Pilz et al. ENVIRONMENTAL RESEARCH
- Effects of BA.1/BA.2 subvariant, vaccination, and prior infection on infectiousness of SARS-CoV-2 omicron infections
- (2022) Suelen H Qassim et al. JOURNAL OF TRAVEL MEDICINE
- Duration of effectiveness of vaccines against SARS-CoV-2 infection and COVID-19 disease: results of a systematic review and meta-regression
- (2022) Daniel R Feikin et al. LANCET
- An early warning system for emerging SARS-CoV-2 variants
- (2022) Lorenzo Subissi et al. NATURE MEDICINE
- Covid-19 Vaccine Effectiveness against the Omicron (B.1.1.529) Variant
- (2022) Nick Andrews et al. NEW ENGLAND JOURNAL OF MEDICINE
- Effect of mRNA Vaccine Boosters against SARS-CoV-2 Omicron Infection in Qatar
- (2022) Laith J. Abu-Raddad et al. NEW ENGLAND JOURNAL OF MEDICINE
- Duration of mRNA vaccine protection against SARS-CoV-2 Omicron BA.1 and BA.2 subvariants in Qatar
- (2022) Hiam Chemaitelly et al. Nature Communications
- Duration of effectiveness of vaccination against COVID-19 caused by the omicron variant
- (2022) Melissa M Higdon et al. LANCET INFECTIOUS DISEASES
- Effects of Previous Infection and Vaccination on Symptomatic Omicron Infections
- (2022) Heba N. Altarawneh et al. NEW ENGLAND JOURNAL OF MEDICINE
- Protection of Omicron sub-lineage infection against reinfection with another Omicron sub-lineage
- (2022) Hiam Chemaitelly et al. Nature Communications
- Immunological characteristics govern the transition of COVID-19 to endemicity
- (2021) Jennie S. Lavine et al. SCIENCE
- Mathematical modeling of the SARS-CoV-2 epidemic in Qatar and its impact on the national response to COVID-19
- (2021) Houssein H Ayoub et al. Journal of Global Health
- Effectiveness of the BNT162b2 Covid-19 Vaccine against the B.1.1.7 and B.1.351 Variants
- (2021) Laith J. Abu-Raddad et al. NEW ENGLAND JOURNAL OF MEDICINE
- Characterizing the Qatar advanced-phase SARS-CoV-2 epidemic
- (2021) Laith J. Abu-Raddad et al. Scientific Reports
- SARS-CoV-2 infection is at herd immunity in the majority segment of the population of Qatar
- (2021) Mohamed H Al-Thani et al. Open Forum Infectious Diseases
- Real-Time SARS-CoV-2 Genotyping by High-Throughput Multiplex PCR Reveals the Epidemiology of the Variants of Concern in Qatar
- (2021) Mohammad R. Hasan et al. INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES
- Pfizer-BioNTech mRNA BNT162b2 Covid-19 vaccine protection against variants of concern after one versus two doses
- (2021) Laith J Abu-Raddad et al. JOURNAL OF TRAVEL MEDICINE
- mRNA-1273 COVID-19 vaccine effectiveness against the B.1.1.7 and B.1.351 variants and severe COVID-19 disease in Qatar
- (2021) Hiam Chemaitelly et al. NATURE MEDICINE
- SARS-CoV-2 infection hospitalization, severity, criticality, and fatality rates in Qatar
- (2021) Shaheen Seedat et al. Scientific Reports
- SARS-CoV-2 seroprevalence in the urban population of Qatar: An analysis of antibody testing on a sample of 112,941 individuals
- (2021) Peter V. Coyle et al. iScience
- A Systematic Review of the Protective Effect of Prior SARS-CoV-2 Infection on Repeat Infection
- (2021) N. Kojima et al. EVALUATION & THE HEALTH PROFESSIONS
- Association of Prior SARS-CoV-2 Infection With Risk of Breakthrough Infection Following mRNA Vaccination in Qatar
- (2021) Laith J. Abu-Raddad et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Comparison of antibody immune responses between BNT162b2 and mRNA-1273 SARS-CoV-2 vaccines in naïve and previously infected individuals
- (2021) Duaa W Al-Sadeq et al. JOURNAL OF TRAVEL MEDICINE
- Effectiveness of a third dose of the BNT162b2 mRNA COVID-19 vaccine for preventing severe outcomes in Israel: an observational study
- (2021) Noam Barda et al. LANCET
- Severity of SARS-CoV-2 Reinfections as Compared with Primary Infections
- (2021) Laith J. Abu-Raddad et al. NEW ENGLAND JOURNAL OF MEDICINE
- Efficacy of Natural Immunity against SARS-CoV-2 Reinfection with the Beta Variant
- (2021) Hiam Chemaitelly et al. NEW ENGLAND JOURNAL OF MEDICINE
- Waning of BNT162b2 Vaccine Protection against SARS-CoV-2 Infection in Qatar
- (2021) Hiam Chemaitelly et al. NEW ENGLAND JOURNAL OF MEDICINE
- Introduction and expansion of the SARS-CoV-2 B.1.1.7 variant and reinfections in Qatar: A nationally representative cohort study
- (2021) Laith J. Abu-Raddad et al. PLOS MEDICINE
- One Year of SARS-CoV-2: Genomic Characterization of COVID-19 Outbreak in Qatar
- (2021) Fatiha M. Benslimane et al. Frontiers in Cellular and Infection Microbiology
- Immune-mediated attenuation of influenza illness after infection: opportunities and challenges
- (2021) Manish M Patel et al. Lancet Microbe
- Projecting the transmission dynamics of SARS-CoV-2 through the postpandemic period
- (2020) Stephen M. Kissler et al. SCIENCE
- Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
- (2020) Fernando P. Polack et al. NEW ENGLAND JOURNAL OF MEDICINE
- Depletion of Susceptibles Bias in Analyses of Intra-season Waning of Influenza Vaccine Effectiveness
- (2019) G Thomas Ray et al. CLINICAL INFECTIOUS DISEASES
- Using Big Data to Emulate a Target Trial When a Randomized Trial Is Not Available: Table 1.
- (2016) Miguel A. Hernán et al. AMERICAN JOURNAL OF EPIDEMIOLOGY
- Longevity and Determinants of Protective Humoral Immunity after Pandemic Influenza Infection
- (2015) Saranya Sridhar et al. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE
- The eradication of smallpox – An overview of the past, present, and future
- (2011) Donald A. Henderson VACCINE
- Using the Standardized Difference to Compare the Prevalence of a Binary Variable Between Two Groups in Observational Research
- (2009) Peter C. Austin COMMUNICATIONS IN STATISTICS-SIMULATION AND COMPUTATION
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started